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Breast Cancer Vaccine: Are We There Yet?
Abstract
In lieu of an abstract, here is the article's first paragraph:
Breast cancer is the most fatal form of cancer for female population worldwide. National Cancer Institute
(NCI) estimates 226,870 females and 2,190 males to be diagnosed with breast cancer in the United
States by the end of 2012. The estimated death toll for this year includes 39,510 females and 410 males,
as reported by NCI. Statistics state that 1 in every 8 females will be diagnosed with breast cancer during
her lifetime. These alarming numbers have provoked a large number of scientists to contribute towards
the fight against breast cancer. Today there are various tools available for females to protect them from
breast cancer. Mammography serves as an efficient tool in screening and catching such cases early
enough for improved treatment, while surgery, radiotherapy and chemotherapy provide a strong line of
treatment to breast cancer patients. Cancer patients are often subjected to a combination of such
therapies, leading to cumulative adverse effects accompanied with the treatment. Addressing the growing
number of breast cancer cases, the adverse effects associated with current therapies and the risk of
having a relapse after undergoing extensive conventional therapy, researchers are now looking forward
for a breast cancer vaccine [1-3].
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Breast Cancer Vaccine: Are We There Yet?
Lipika Chablani*
Wegmans School of Pharmacy, St. John Fisher College, 3690 East Ave, Rochester, NY 14618, USA

Editorial
Breast cancer is the most fatal form of cancer for female population
worldwide. National Cancer Institute (NCI) estimates 226,870 females
and 2,190 males to be diagnosed with breast cancer in the United States
by the end of 2012. The estimated death toll for this year includes 39,510
females and 410 males, as reported by NCI. Statistics state that 1 in
every 8 females will be diagnosed with breast cancer during her lifetime.
These alarming numbers have provoked a large number of scientists
to contribute towards the fight against breast cancer. Today there are
various tools available for females to protect them from breast cancer.
Mammography serves as an efficient tool in screening and catching such
cases early enough for improved treatment, while surgery, radiotherapy
and chemotherapy provide a strong line of treatment to breast cancer
patients. Cancer patients are often subjected to a combination of such
therapies, leading to cumulative adverse effects accompanied with the
treatment. Addressing the growing number of breast cancer cases, the
adverse effects associated with current therapies and the risk of having
a relapse after undergoing extensive conventional therapy, researchers
are now looking forward for a breast cancer vaccine [1-3].
So far vaccines have been very effectively employed to prevent the
infectious diseases, but the role of vaccines against cancer still remains
to be explored. Infectious diseases are caused by pathogens, which are
foreign in origin and thus immunizing the body to recognize these
non-self invaders is relatively a less daunting task. However, cancer
originates by uncontrolled growth of own cells, thus immunizing the
body against such self-antigens is a challenge. This strongly correlates
with the fact that we have only one US Food and Drug Administration
(FDA) approved cancer vaccine available to us currently. Provenge/
Sipuleucel-T (Dendreon Corporation, Washington) is the only FDA
approved therapeutic cancer vaccine against prostate cancer. Which
involves activation of dendritic cells in presence of a prostate cancer
antigen along with an immunostimulant. This vaccine has shown a
marginal increase in the life span of prostate cancer patients by on an
average of four months at a cost of $93,000. Dendreon Corporation is
currently evaluating this approach to develop a breast cancer vaccine,
Neuvenge/Lapuleucel-T, which uses the Human Epidermal growth
factor Receptor 2 (HER 2) antigen as the immunogenic component of
the vaccine b [4].
The HER 2 antigen has also been explored as the source of E75
peptide vaccine, which is currently under Phase III clinical trial. The
E75 peptide/NeuVax™ vaccine is a promising clinical trial offering
hope to breast and ovarian cancer patients having HER 2 positive
tumors [5]. Even the patients, whose HER 2 antigen expression is
low (Immunohistochemisty [IHC] score of 1+/2+) can benefit from
this vaccine. Such patients could not benefit from the well-received
antibody therapy of Herceptin and contributed to two-third of HER
2+ breast cancer population. NeuVax™ aims to target breast cancer
survivors with healthy immune system, providing ample opportunity
to the vaccine to elicit its response [3].
Several other breast cancer antigens such as Mucin 1 (MUC1),
human telomerase reverse transcriptase (hTERT), tumor protein 53
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(p53), and cancer embryonic antigen (CEA) have been identified and
employed as vaccines as well. Thus, various researchers have explored
different breast cancer vaccines in the quest of finding the one, which
can benefit the breast cancer patients.
On similar lines, Chablani and D’Souza et al., proposes the
preparation of breast cancer vaccines, formulated in a particulate
delivery system [6]. The immune response elicited by a vaccine not
only depends on the immunogenicity of the antigen, but also the mode
of antigen presentation [7]. A particulate delivery system enhances the
antigen presentation of such antigenic components, thus leading to
an efficacious vaccine. The author has reported the use of particulate
delivery system to prepare an oral murine breast cancer vaccine, which
was successfully tested in a female Balb/c mice model. Oral route of
vaccine administration appears to be lucrative not only due to ease of
administration but also due to the availability of specialized phagocytic
M-cells present in Peyer’s patches of small intestine. These M-cells
specialize in sampling pathogens from gut and present them to the
immune cells housed beneath them [8,9]. Thus having a particulate
oral breast cancer vaccine sampled by the M-cells leads to induction
of both cellular and humoral immunity, as shown by the author.
This oral murine breast cancer vaccine has been successfully tested
as a prophylactic approach and currently the group is evaluating the
efficacy of this vaccine therapeutically.
Another alternate route of administration, which has been explored
for influenza vaccine, recently, is the transdermal route. The vaccine
is administered via skin with the aid of micron-sized needles [10].
These microneedles, when applied on skin, painlessly create aqueous
conduits, which can be used to deliver the vaccine into the epidermis.
The epidermis hosts various antigen-presenting cells (Langerhans
cells), which are capable of activating immune cells to generate
protective immunity. Chablani and D’Souza et al. have also explored
this route of administration for an efficacious particulate murine breast
cancer vaccine (data not yet published). Transdermal route of breast
cancer vaccination did result in a protective immune response against
tumor challenge as evaluated in a prophylactic vaccine study by the
Chablani and D’Souza et al.
Considering the advent of nanotechnology and the advances in the
field of immunotherapy, we hope to have an efficacious breast cancer
vaccine soon.
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